MAX Chat
Company Analysis Sino Biopharmaceutical Limited
1. Summary
Advantages
- Dividends (3.05%) are higher than the sector average (2.28%).
- The stock's return over the last year (90.84%) is higher than the sector average (4.54%).
Disadvantages
- Price (0.729 $) is higher than fair price (0.4845 $)
- Current debt level 14.96% has increased over 5 years from 14.71%.
- The company's current efficiency (ROE=11.21%) is lower than the sector average (ROE=12.46%)
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| Sino Biopharmaceutical Limited | Healthcare | Index | |
|---|---|---|---|
| 7 days | 31.8% | 0% | 1.5% |
| 90 days | 60.6% | -1.1% | 23.1% |
| 1 year | 90.8% | 4.5% | 13.8% |
SBMFF vs Sector: Sino Biopharmaceutical Limited has outperformed the "Healthcare" sector by 86.3% over the past year.
SBMFF vs Market: Sino Biopharmaceutical Limited has outperformed the market by 77% over the past year.
Stable price: SBMFF is not significantly more volatile than the rest of the market on "OTC" over the last 3 months, with typical variations of +/- 5% per week.
Long period: SBMFF with weekly volatility of 1.75% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (0.729 $) is higher than the fair price (0.4845 $).
Price is higher than fair: The current price (0.729 $) is 33.5% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (15.68) is lower than that of the sector as a whole (54.24).
P/E vs Market: The company's P/E (15.68) is lower than that of the market as a whole (59.87).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (1.28) is lower than that of the sector as a whole (4.2).
P/BV vs Market: The company's P/BV (1.28) is lower than that of the market as a whole (3.17).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (1.9) is lower than that of the sector as a whole (4.62).
P/S vs Market: The company's P/S indicator (1.9) is lower than that of the market as a whole (3.43).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (9.02) is lower than that of the sector as a whole (14.71).
EV/Ebitda vs Market: The company's EV/Ebitda (9.02) is lower than that of the market as a whole (40.12).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Rising and has grown by 5.26% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (5.26%).
Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (0.5351%).
5.4. ROE
ROE vs Sector: The company's ROE (11.21%) is lower than that of the sector as a whole (12.46%).
ROE vs Market: The company's ROE (11.21%) is lower than that of the market as a whole (41.73%).
5.5. ROA
ROA vs Sector: The company's ROA (5.43%) is lower than that of the sector as a whole (6.23%).
ROA vs Market: The company's ROA (5.43%) is lower than that of the market as a whole (29.55%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (40.18%) is higher than that of the sector as a whole (15.34%).
ROIC vs Market: The company's ROIC (40.18%) is higher than that of the market as a whole (10.99%).
7. Dividends
7.1. Dividend yield vs Market
High yield: The dividend yield of the company 3.05% is higher than the average for the sector '2.28%.
7.2. Stability and increase in payments
Dividend stability: The company's dividend yield 3.05% has been steadily paid over the past 7 years, DSI=0.79.
Weak dividend growth: The company's dividend yield 3.05% has been growing weakly or stagnant over the past 5 years. Growth over only 2 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (52.76%) are at a comfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
